Alexion is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. Alexion established operations in Sydney in 2008 to serve patients in the Australian region. We aim to work in partnership with stakeholders including healthcare providers, patient advocacy organisations, and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we aim to help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.
In Australia, SOLIRIS® (eculizumab rmc) is registered for the treatment of atypical haemolytic uraemic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria (PNH), and for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. These three are devastating, ultra-rare, complement-mediated diseases. SOLIRIS is reimbursed under the Pharmaceutical Benefits Scheme (PBS) Section 100 Highly Specialised Drugs Program for aHUS and PNH. For the treatment of NMOSD, SOLIRIS is not reimbursed on the PBS. Product Information for SOLIRIS can be accessed here and Consumer Medicine Information here.
ULTOMIRIS® (ravulizumab rch) is registered in Australia for the treatment of PNH. ULTOMIRIS is reimbursed under the Pharmaceutical Benefits Scheme Section 100 Highly Specialised Drugs Program for PNH. Product information can be accessed here and Consumer Medicine Information here.
STRENSIQ® (asfotase alfa rch) is registered in Australia for the treatment of paediatric-onset hypophosphatasia (HPP). STRENSIQ is funded under the Life Saving Drugs Program for perinatal or infantile-onset HPP. Product Information for STRENSIQ can be accessed here and Consumer Medicine Information here.
Alexion is committed to seeking government reimbursement for KANUMA® (sebelipase alfa rce) registered in Australia for the treatment of lysosomal acid lipase deficiency (LAL-D), a severe, ultra-rare metabolic disease. Product information for KANUMA can be accessed here and Consumer Medicine Information here.
How We Engage With Patients
We seek to understand and incorporate insights from people living with rare diseases and their caregivers into our development plans, medicines, and services. Our promise is to partner with the rare disease community to understand the patient experience as they search for diagnosis, treatment, disease education, and condition management. We work closely with patient advocacy groups and through direct patient engagements to realise shared ambitions whilst respecting the privacy and independence of all parties.
Everyday, we serve people living with rare and devastating diseases. Groundbreaking innovation and life-saving therapies, all driven by a team with a shared sense of purpose and dedication — that’s Alexion.
Join us to help patients and their families fully live their best lives. Browse job openings in Australia here: